The so-called “integrated diagnosis” combining the histological tumor typing, tumor grading using the four-tiered WHO grading scheme, and the tissue-based molecular analyses of IDH mutations and other molecular characteristics represents now the standard in the diagnostic process of CNS astrocytic and oligodendroglial tumors, including GBM [17, 18]. This evidence concerns the gene IDH1 and oligodendroglial tumor.